I. O. Rutkin
I. O. Rutkin has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Dmitrii A. Granov
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies
12 shared publications - Aleksey Aleksandrovich Polikarpov
ФГБУ «Российский научный центр радиологии и хирургических технологий им. акад. А.М. Гранова» МЗ РФ
4 shared publications - I. I. Tileubergenov
A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies
4 shared publications - A. A. Koroleva
Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia
3 shared publications - Dmitry Kovalenko
Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia
3 shared publications - Mikhail G. Efanov
Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia
3 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 31 (3) , 54-58
Liver transplantation combined with pancreatoduodenal resection inbcases of Klatskin tumor
This study presents a clinical case report on the successful performance of simultaneous liver transplantation and pancreatoduodenal resection as part of a combined treatment regimen for an unresectable Klatskin tumor. The follow-up periods from the start of treatment and surgery were 22 and 10 months, respectively. This article emphasizes key stages of combination therapy for patients in this category, focusing on significant surgical aspects.
- 5 October 2026
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 31 (3) , 54-58
Open AccessLiver transplantation combined with pancreatoduodenal resection inbcases of Klatskin tumor
This study presents a clinical case report on the successful performance of simultaneous liver transplantation and pancreatoduodenal resection as part of a combined treatment regimen for an unresectable Klatskin tumor. The follow-up periods from the start of treatment and surgery were 22 and 10 months, respectively. This article emphasizes key stages of combination therapy for patients in this category, focusing on significant surgical aspects.
- Open Access
- 9 June 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 33 (1) , 75-83
Potential of Dual-Phase 68Ga-FAPI PET/CT in the Differential Diagnosis of Focal Liver Lesions
Introduction. Recent studies have confirmed the effectiveness of positron emission tomography combined with computed tomography (PET/CT) using radiolabeled ligands of fibroblast activation protein inhibitors (FAPI) for the visualization of malignant lesions (ML) and benign lesions (BL). The objective was to evaluate the diagnostic utility of dual-phase PET/CT with 68 Ga-FAPI-04 in patients with focal liver lesions of varying etiology. Methods and materials. The study enrolled 62 patients with focal liver lesions of diverse etiologies for the purpose of differential diagnosis (20/62 patients) and pretreatment staging (42/62 patients). 68 Ga-FAPI-04 PET/CT imaging was performed in two phases: Phase I (PET/CT 20 ) – imaging began 20 minutes after administration of 68 Ga-FAPI-04 (limited to the abdominal region); Phase II (PET/CT 60 ) – 60 minutes after injection, performed as a «Whole-body» scan. Image analysis included visual assessment and calculation of the maximum standardized uptake value (SUVmax) over the lesion areas. Results. Comprehensive clinical and imaging evaluation identified a total of 128 focal liver lesions. At the early-phase PET/CT scan (PET/CT 20 ), increased 68 Ga-FAPI-04 uptake was observed in 109 of 128 lesions (85.2 %): 18 of 25 BL and 91 of 103 ML. A comparable uptake pattern was seen on the delayed-phase scan (PET/CT 60 ): 18 of 25 BL and 93 of 103 ML. Visual and quantitative analyses of dual-phase 68 Ga-FAPI-04 PET/CT demonstrated no significant differences in sensitivity, specificity, and diagnostic accuracy between phase I and phase II for the differential diagnosis of focal liver lesions. Visual assessment yielded values of 88.3 %, 28 %, 76.6 % for phase I versus 90.3 %, 28 %, 78.1 % for phase II. Quantitative analysis of 68 Ga-FAPI-04 uptake intensity in hepatic lesions showed corresponding values of 73.8 %, 64 %, 74.2 % for phase I and 68 %, 72 %, 71.6 % for phase II. Conclusion: Elevated 68 Ga-FAPI-04 uptake was observed in the majority of hepatic lesions during both early and delayed imaging phases, irrespective of lesion etiology. Given the absence of significant diagnostic gain between time points, dual-phase PET/CT acquisition appears unnecessary for differentiating the etiology of liver lesions. Quantitative assessment using SUVmax values contributes to improved specificity of 68 Ga-FAPI-04 PET/CT in identifying malignant hepatic involvement.
- 9 June 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 33 (1) , 75-83
Open AccessPotential of Dual-Phase 68Ga-FAPI PET/CT in the Differential Diagnosis of Focal Liver Lesions
Introduction. Recent studies have confirmed the effectiveness of positron emission tomography combined with computed tomography (PET/CT) using radiolabeled ligands of fibroblast activation protein inhibitors (FAPI) for the visualization of malignant lesions (ML) and benign lesions (BL). The objective was to evaluate the diagnostic utility of dual-phase PET/CT with 68 Ga-FAPI-04 in patients with focal liver lesions of varying etiology. Methods and materials. The study enrolled 62 patients with focal liver lesions of diverse etiologies for the purpose of differential diagnosis (20/62 patients) and pretreatment staging (42/62 patients). 68 Ga-FAPI-04 PET/CT imaging was performed in two phases: Phase I (PET/CT 20 ) – imaging began 20 minutes after administration of 68 Ga-FAPI-04 (limited to the abdominal region); Phase II (PET/CT 60 ) – 60 minutes after injection, performed as a «Whole-body» scan. Image analysis included visual assessment and calculation of the maximum standardized uptake value (SUVmax) over the lesion areas. Results. Comprehensive clinical and imaging evaluation identified a total of 128 focal liver lesions. At the early-phase PET/CT scan (PET/CT 20 ), increased 68 Ga-FAPI-04 uptake was observed in 109 of 128 lesions (85.2 %): 18 of 25 BL and 91 of 103 ML. A comparable uptake pattern was seen on the delayed-phase scan (PET/CT 60 ): 18 of 25 BL and 93 of 103 ML. Visual and quantitative analyses of dual-phase 68 Ga-FAPI-04 PET/CT demonstrated no significant differences in sensitivity, specificity, and diagnostic accuracy between phase I and phase II for the differential diagnosis of focal liver lesions. Visual assessment yielded values of 88.3 %, 28 %, 76.6 % for phase I versus 90.3 %, 28 %, 78.1 % for phase II. Quantitative analysis of 68 Ga-FAPI-04 uptake intensity in hepatic lesions showed corresponding values of 73.8 %, 64 %, 74.2 % for phase I and 68 %, 72 %, 71.6 % for phase II. Conclusion: Elevated 68 Ga-FAPI-04 uptake was observed in the majority of hepatic lesions during both early and delayed imaging phases, irrespective of lesion etiology. Given the absence of significant diagnostic gain between time points, dual-phase PET/CT acquisition appears unnecessary for differentiating the etiology of liver lesions. Quantitative assessment using SUVmax values contributes to improved specificity of 68 Ga-FAPI-04 PET/CT in identifying malignant hepatic involvement.
- Open Access
- 9 May 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (1) , 92-99
Clinical case of locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus treated with VEGFR-TKI/IO combination pembrolizumab + lenvatinib
The article presents a clinical case of treatment of a young man with locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus above the diaphragm. Due to non-standard neoadjuvant approach of using modern tyrosine kinase inhibitors of VEGFR and immunotherapy (VEGFR-TKI/IO) combination pembrolizumab + lenvatinib, thoracotomy was avoided and complete pathological regression of the tumor was achieved. Various studies on neoadjuvant therapy of kidney cancer including in patients with tumor thrombus are discussed, and the prospects for introducing this approach into clinical practice are described.
- 9 May 2025
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (1) , 92-99
Open AccessClinical case of locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus treated with VEGFR-TKI/IO combination pembrolizumab + lenvatinib
The article presents a clinical case of treatment of a young man with locally advanced renal cell carcinoma with an inferior vena cava tumor thrombus above the diaphragm. Due to non-standard neoadjuvant approach of using modern tyrosine kinase inhibitors of VEGFR and immunotherapy (VEGFR-TKI/IO) combination pembrolizumab + lenvatinib, thoracotomy was avoided and complete pathological regression of the tumor was achieved. Various studies on neoadjuvant therapy of kidney cancer including in patients with tumor thrombus are discussed, and the prospects for introducing this approach into clinical practice are described.
- 4 February 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 5-13
Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma
Objective. To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC). Material and methods. We analyzed the results of surgical and combined treatment of IHCC between 1999 and 2023. Immediate and long-term outcomes were evaluated depending on negative prognostic factors and additional therapy. Results. The study included 195 patients. Postoperative complications grade ≥III were observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent treatment before surgery, 109 (55.9%) ones — after surgery. The median overall survival was 31 months, 5-year overall survival — 32.0%. The following factors worsened overall survival: node size ≥8 cm (HR 1.45; 95% CI 0.97—2.17), invasion (HR 1.63; 95% CI 1.07—2.47), multiple lesion (HR 1.51; 95% CI 1.00—2.28). R1 resection worsened disease-free survival (HR 1.88; 95% CI 1.14—3.10). Lymph node metastases decreased overall (HR 1.96; 95% CI 1.27- 3.04) and disease-free survival (HR 2.37; 95% CI 1.63—3.44). Two and more negative factors worsened overall (p=0.0013) and disease-free survival (p=0.0005). Absence of adjuvant therapy worsened overall (HR 2.12; 95% CI 1.41—3.20) and disease-free survival (HR 1.42; 95% CI 0.99—2.04). There was a trend towards higher overall (p=0.088) and progression-free survival (p=0.029) in case of preoperative therapy (n=195). In unfavorable prognosis group, preoperative therapy (n=33) was superior to standard treatment (resection+capecitabine after surgery, n=26). There was a trend towards higher overall survival (p=0.066) and significantly better progression-free survival (17 vs 13 months, p=0.018). Conclusion. Negative prognostic factors for resectable IHCC are lesion size ≥8 cm, intrahepatic and regional metastases, invasion into neighboring structures, R1 resection. Combination of negative factors worsened prognosis. Adjuvant therapy improved postoperative outcomes. Preoperative therapy may be advisable in case of negative factors and high risk of R1 resection.
- 4 February 2025
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 5-13
Prognostic factors and preoperative therapy in resectable intrahepatic cholangiocarcinoma
Objective. To identify prognostic factors and role of preoperative therapy for resectable intrahepatic cholangiocarcinoma (IHCC). Material and methods. We analyzed the results of surgical and combined treatment of IHCC between 1999 and 2023. Immediate and long-term outcomes were evaluated depending on negative prognostic factors and additional therapy. Results. The study included 195 patients. Postoperative complications grade ≥III were observed in 35 (17.9%) case. Mortality rate was 3.1% (n=6). Thirty-eight patients (19.5%) underwent treatment before surgery, 109 (55.9%) ones — after surgery. The median overall survival was 31 months, 5-year overall survival — 32.0%. The following factors worsened overall survival: node size ≥8 cm (HR 1.45; 95% CI 0.97—2.17), invasion (HR 1.63; 95% CI 1.07—2.47), multiple lesion (HR 1.51; 95% CI 1.00—2.28). R1 resection worsened disease-free survival (HR 1.88; 95% CI 1.14—3.10). Lymph node metastases decreased overall (HR 1.96; 95% CI 1.27- 3.04) and disease-free survival (HR 2.37; 95% CI 1.63—3.44). Two and more negative factors worsened overall (p=0.0013) and disease-free survival (p=0.0005). Absence of adjuvant therapy worsened overall (HR 2.12; 95% CI 1.41—3.20) and disease-free survival (HR 1.42; 95% CI 0.99—2.04). There was a trend towards higher overall (p=0.088) and progression-free survival (p=0.029) in case of preoperative therapy (n=195). In unfavorable prognosis group, preoperative therapy (n=33) was superior to standard treatment (resection+capecitabine after surgery, n=26). There was a trend towards higher overall survival (p=0.066) and significantly better progression-free survival (17 vs 13 months, p=0.018). Conclusion. Negative prognostic factors for resectable IHCC are lesion size ≥8 cm, intrahepatic and regional metastases, invasion into neighboring structures, R1 resection. Combination of negative factors worsened prognosis. Adjuvant therapy improved postoperative outcomes. Preoperative therapy may be advisable in case of negative factors and high risk of R1 resection.
- Open Access
- 26 December 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (4) , 86-92
Combined Treatment of Patients with Neuroendocrine Liver Metastases Accompanied by High Hormonal Activity and Uncontrolled Carcinoid Syndrome
Introduction: The percentage of cases of neuroendocrine tumors (NET) is growing every year. Moreover, the diagnosis is often made in the later stages, when the disease manifests itself with manifestations of carcinoid syndrome (CS) and its accompanying indications. Today, there is a need to systematize approaches to diagnosis and individual groups of patients with unresectable metastatic lesions of NETs.Material and methods: A retrospective assessment of the results of treatment of patients with bilobar metastatic liver disease NET on the background of uncontrolled CS was performed in the period from 2010 to 2023. The study included 10 patients with NET G1 — 4 patients, G2 — 6. The sampling structure according to the location of the primary lesion was divided into: pancreas (n = 7), small intestine (n = 3). Before the start of regional chemotherapy, the primary lesion was removed in 1 patient. The average age of the patients in the sample was 31.3 years.In order to evaluate the results, patients underwent SCT of the abdominal cavity and chest with intravenous enhancement, PET/CT of the whole body with 68Ga-DOTA TATE/NOC. All patients in the group received therapy with long-acting somatostatin analogues. Two of them additionally received everolimus 10 mg per day.The leading method of embolization is oil TACE with a suspension of doxorubicin 50–100 mg or mitomycin C 10–20 mg with superfluid lipiodol 5–8 ml, then adding a collagen sponge 0.25–0.5 cm3 into the tumor vessels until blood flow is reduced. Courses were held once every 2 months. The evaluation of the treatment was carried out according to an objective examination (ECOG 0), the nature of the complaints, and instrumental diagnostic data (CT with intravenous contrast).Results: Evaluation after regional chemotherapy: partial response in one patient; stabilization in seven; progression in two patients (according to mRECIST). The average serotonin level before CEPA was 936.5 ng/ml; after two courses there was a significant decrease to 282.1 ng/ml (p < 0.05). After stabilization of the disease, the primary lesion was removed in 6 patients; patients underwent cytoreductive atypical liver resection (n = 4) and MVA (n = 1). Currently, three patients have died, the average life expectancy of the deceased is 64 months. Seven patients were alive for periods ranging from 30 to 134 (median 84) months.Conclusions : TACE in the treatment of patients with NETs that cause hyperproduction of hormones, manifested by CS and not relieved by somatostatin analogues, provides clinical and radiological improvements in 80 % of patients. Further cytoreductive interventions can extend the median overall-survival (OS) to 84 months.
- 26 December 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (4) , 86-92
Open AccessCombined Treatment of Patients with Neuroendocrine Liver Metastases Accompanied by High Hormonal Activity and Uncontrolled Carcinoid Syndrome
Introduction: The percentage of cases of neuroendocrine tumors (NET) is growing every year. Moreover, the diagnosis is often made in the later stages, when the disease manifests itself with manifestations of carcinoid syndrome (CS) and its accompanying indications. Today, there is a need to systematize approaches to diagnosis and individual groups of patients with unresectable metastatic lesions of NETs.Material and methods: A retrospective assessment of the results of treatment of patients with bilobar metastatic liver disease NET on the background of uncontrolled CS was performed in the period from 2010 to 2023. The study included 10 patients with NET G1 — 4 patients, G2 — 6. The sampling structure according to the location of the primary lesion was divided into: pancreas (n = 7), small intestine (n = 3). Before the start of regional chemotherapy, the primary lesion was removed in 1 patient. The average age of the patients in the sample was 31.3 years.In order to evaluate the results, patients underwent SCT of the abdominal cavity and chest with intravenous enhancement, PET/CT of the whole body with 68Ga-DOTA TATE/NOC. All patients in the group received therapy with long-acting somatostatin analogues. Two of them additionally received everolimus 10 mg per day.The leading method of embolization is oil TACE with a suspension of doxorubicin 50–100 mg or mitomycin C 10–20 mg with superfluid lipiodol 5–8 ml, then adding a collagen sponge 0.25–0.5 cm3 into the tumor vessels until blood flow is reduced. Courses were held once every 2 months. The evaluation of the treatment was carried out according to an objective examination (ECOG 0), the nature of the complaints, and instrumental diagnostic data (CT with intravenous contrast).Results: Evaluation after regional chemotherapy: partial response in one patient; stabilization in seven; progression in two patients (according to mRECIST). The average serotonin level before CEPA was 936.5 ng/ml; after two courses there was a significant decrease to 282.1 ng/ml (p < 0.05). After stabilization of the disease, the primary lesion was removed in 6 patients; patients underwent cytoreductive atypical liver resection (n = 4) and MVA (n = 1). Currently, three patients have died, the average life expectancy of the deceased is 64 months. Seven patients were alive for periods ranging from 30 to 134 (median 84) months.Conclusions : TACE in the treatment of patients with NETs that cause hyperproduction of hormones, manifested by CS and not relieved by somatostatin analogues, provides clinical and radiological improvements in 80 % of patients. Further cytoreductive interventions can extend the median overall-survival (OS) to 84 months.
- Open Access
- 30 November 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (5)
Influence of Preoperative Hepatic Artery Chemoembolization on Long-Term Oncological Outcomes after Liver Resection for Hepatocellular Carcinoma and Assessment of Predictors of Recurrence
Цель. Оценить роль предоперационной химиоэмболизации печеночной артерии и выявить предикторы развития рецидива гепатоцеллюлярной карциномы после радикальных резекций. Материалы и методы. С 2011 по 2022 гг. выполнено 80 резекций печени по поводу гепатоцеллюлярной карциномы на фоне цирроза печени А. Чайлд-Пью. У 36 пациентов хирургическому вмешательству предшествовала химиоэмболизация печеночной артерии от одного до 4 циклов с последующей оценкой ответа по m-RECIST и динамики альфа-фетопротеина. У 44 пациентов резекция выполнена без неоадъювантного лечения. У всех пациентов оценивалась степень дифференцировки опухоли. Результаты. Частота пострезекционной печеночной недостаточности и послеоперационных осложнений в двух группах достоверно не различалась (p > 0,05). В обеих группах при низкодифференцированной опухоли рецидив возник в 100 % случаев, умеренно дифференцированной — в 84 %, высоко дифференцированной — в 50 % (p < 0,05). В основной группе рост АФП приводил к рецидиву в 100 % случаев, у пациентов со снижением онкомаркера — в 59 % (p < 0,05). В основной группе при полном ответе по mRECIST рецидива не отмечено, при частичном ответе — рецидив в 45 % случаев, при стабилизации заболевания — 82 %, при прогрессировании — в 100 % (p < 0,05). Медианы безрецидивной и общей выживаемости в группах с предоперационным лечением и без него составили 10 и 15,5 месяцев, 72 и 48 месяцев соответственно. Выводы. Предоперационная химиоэмболизация при гепатоцеллюлярной карциноме безопасна, увеличивает медиану общей выживаемости после резекции. Рост АФП, отсутствие полного или частичного ответа по mRECIST в группе с предоперационным лечением и низкая степень дифференцировки в обеих группах являются предикторами рецидива после радикальных резекций печени.
- 30 November 2024
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 70 (5)
Open AccessInfluence of Preoperative Hepatic Artery Chemoembolization on Long-Term Oncological Outcomes after Liver Resection for Hepatocellular Carcinoma and Assessment of Predictors of Recurrence
Цель. Оценить роль предоперационной химиоэмболизации печеночной артерии и выявить предикторы развития рецидива гепатоцеллюлярной карциномы после радикальных резекций. Материалы и методы. С 2011 по 2022 гг. выполнено 80 резекций печени по поводу гепатоцеллюлярной карциномы на фоне цирроза печени А. Чайлд-Пью. У 36 пациентов хирургическому вмешательству предшествовала химиоэмболизация печеночной артерии от одного до 4 циклов с последующей оценкой ответа по m-RECIST и динамики альфа-фетопротеина. У 44 пациентов резекция выполнена без неоадъювантного лечения. У всех пациентов оценивалась степень дифференцировки опухоли. Результаты. Частота пострезекционной печеночной недостаточности и послеоперационных осложнений в двух группах достоверно не различалась (p > 0,05). В обеих группах при низкодифференцированной опухоли рецидив возник в 100 % случаев, умеренно дифференцированной — в 84 %, высоко дифференцированной — в 50 % (p < 0,05). В основной группе рост АФП приводил к рецидиву в 100 % случаев, у пациентов со снижением онкомаркера — в 59 % (p < 0,05). В основной группе при полном ответе по mRECIST рецидива не отмечено, при частичном ответе — рецидив в 45 % случаев, при стабилизации заболевания — 82 %, при прогрессировании — в 100 % (p < 0,05). Медианы безрецидивной и общей выживаемости в группах с предоперационным лечением и без него составили 10 и 15,5 месяцев, 72 и 48 месяцев соответственно. Выводы. Предоперационная химиоэмболизация при гепатоцеллюлярной карциноме безопасна, увеличивает медиану общей выживаемости после резекции. Рост АФП, отсутствие полного или частичного ответа по mRECIST в группе с предоперационным лечением и низкая степень дифференцировки в обеих группах являются предикторами рецидива после радикальных резекций печени.
- 18 October 2024
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 10,p. 7-20
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma was prepared by the group of experts consisting of surgeons, interventional radiologists, radiation therapists and oncologists. The purposes of this consensus are clarification and consolidation of opinions of multidisciplinary team on the following issues of management of patients with intrahepatic cholangiocarcinoma: indications for surgical treatment, features of therapeutic tactics for mechanical jaundice, technical aspects of liver resection, prevention of post-resection liver failure, indications for liver resection using transplantation technologies, laparoscopic and robot-assisted liver resection, perioperative systemic chemotherapy, local non-resection/non-radiotherapy methods of treatment, radiotherapy, follow-up and choice of treatment for recurrence.
- 18 October 2024
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 10,p. 7-20
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma was prepared by the group of experts consisting of surgeons, interventional radiologists, radiation therapists and oncologists. The purposes of this consensus are clarification and consolidation of opinions of multidisciplinary team on the following issues of management of patients with intrahepatic cholangiocarcinoma: indications for surgical treatment, features of therapeutic tactics for mechanical jaundice, technical aspects of liver resection, prevention of post-resection liver failure, indications for liver resection using transplantation technologies, laparoscopic and robot-assisted liver resection, perioperative systemic chemotherapy, local non-resection/non-radiotherapy methods of treatment, radiotherapy, follow-up and choice of treatment for recurrence.
- Open Access
- 30 September 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (3) , 70-80
Liver transplantation for unresectable Klatskin tumor: experience of two centers, first distant results
Aim. Evaluation of the first distant results of the combined experience of liver transplantation for unresectable portal cholangiocarcinoma from two large specialized clinical centers.Materials and methods. In total, 23 attempts at liver transplantation for unresectable Klatskin tumor were undertaken. Out of them, 10 were conducted at the A.M. Granov Russian Research Center for Radiology and Surgical Technologies (Granov Center), and 13 were conducted at the Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology (Minsk Center). The maximum tumor size was 5 and 3 cm in patients operated at the Granov and Minsk Centers, respectively. In the Granov Center, neoadjuvant therapy included a combination of endobiliary photodynamic therapy, regional and systemic chemotherapy. Patients were included in the waiting list only in cases of decreased tumor marker levels and in the absence of disease progression and acute cholangitis. In the Minsk Center, stereotactic radiotherapy was used for neoadjuvant treatment in the absence of active cholangitis; the first 3 patients underwent liver transplantation without prior neoadjuvant treatment.Results. Due to disease progression, six patients were excluded. In three patients at the Mink Center, the diagnosis was not morphologically confirmed after liver transplantation. A total of 14 liver transplantations were performed for unresectable hilar cholangiocarcinoma. After neoadjuvant treatment at the Granov Center, normalization of the CA19-9 marker was observed in four patients, its decrease by 3–4 times was observed in two patients. Liver transplantation was performed in six patients. The average time from the onset of treatment to transplantation was 9.1 months (6–14). Out of the six patients, one was alive for 34 months, with the median overall survival being 22.2 months. Progression was the cause of death in only one patient. Out of the three patients without neoadjuvant treatment at the Minsk Center, two were alive at 16 and 134 months without progression. One patient died after transplantation from disease progression at 24 months. Stereotactic radiotherapy achieved normalization of CA19-9 in four patients; its twofold reduction was observed in one patient. The average time from the onset of treatment to transplantation was six months (3–12). The average CA19-9 tumor marker level by the time of transplantation was 11.3 IU/mL. At 20–26 months, three patients were alive without evidence of disease progression; two patients died of progression after 9 and 59 months.Conclusion. Liver transplantation for unresectable portal cholangiocarcinoma after neoadjuvant treatment regardless of the methods used is highly promising in carefully selected recipients.
- 30 September 2024
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 29 (3) , 70-80
Open AccessLiver transplantation for unresectable Klatskin tumor: experience of two centers, first distant results
Aim. Evaluation of the first distant results of the combined experience of liver transplantation for unresectable portal cholangiocarcinoma from two large specialized clinical centers.Materials and methods. In total, 23 attempts at liver transplantation for unresectable Klatskin tumor were undertaken. Out of them, 10 were conducted at the A.M. Granov Russian Research Center for Radiology and Surgical Technologies (Granov Center), and 13 were conducted at the Minsk Scientific and Practical Center for Surgery, Transplantology, and Hematology (Minsk Center). The maximum tumor size was 5 and 3 cm in patients operated at the Granov and Minsk Centers, respectively. In the Granov Center, neoadjuvant therapy included a combination of endobiliary photodynamic therapy, regional and systemic chemotherapy. Patients were included in the waiting list only in cases of decreased tumor marker levels and in the absence of disease progression and acute cholangitis. In the Minsk Center, stereotactic radiotherapy was used for neoadjuvant treatment in the absence of active cholangitis; the first 3 patients underwent liver transplantation without prior neoadjuvant treatment.Results. Due to disease progression, six patients were excluded. In three patients at the Mink Center, the diagnosis was not morphologically confirmed after liver transplantation. A total of 14 liver transplantations were performed for unresectable hilar cholangiocarcinoma. After neoadjuvant treatment at the Granov Center, normalization of the CA19-9 marker was observed in four patients, its decrease by 3–4 times was observed in two patients. Liver transplantation was performed in six patients. The average time from the onset of treatment to transplantation was 9.1 months (6–14). Out of the six patients, one was alive for 34 months, with the median overall survival being 22.2 months. Progression was the cause of death in only one patient. Out of the three patients without neoadjuvant treatment at the Minsk Center, two were alive at 16 and 134 months without progression. One patient died after transplantation from disease progression at 24 months. Stereotactic radiotherapy achieved normalization of CA19-9 in four patients; its twofold reduction was observed in one patient. The average time from the onset of treatment to transplantation was six months (3–12). The average CA19-9 tumor marker level by the time of transplantation was 11.3 IU/mL. At 20–26 months, three patients were alive without evidence of disease progression; two patients died of progression after 9 and 59 months.Conclusion. Liver transplantation for unresectable portal cholangiocarcinoma after neoadjuvant treatment regardless of the methods used is highly promising in carefully selected recipients.
- Open Access
- 19 March 2023
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 28 (1) , 33-40
Results of liver retransplantations
Результаты повторных трансплантаций печени
- 19 March 2023
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 28 (1) , 33-40
Open AccessResults of liver retransplantations
Результаты повторных трансплантаций печени
- Open Access
- 15 December 2022
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 27 (4) , 23-30
Minimally invasive surgery for hepatocellular carcinoma
Aim. To evaluate outcomes of laparoscopic liver resections in patients with hepatocellular carcinoma (HCC).Materials and methods. 40 endovideosurgical liver resections were performed in patients with HCC in the period of 2011–2021. Concomitant cirrhosis was detected in 36 cases (90%).Results. The average duration of surgery was 158.1 ± 78.6 min. The duration of anatomical lobar resections appeared to be the longest – 230 min. The average volume of intraoperative blood loss was 259.5 ± 260.5 ml, which almost excluded blood transfusions. The duration of hospitalization comprised 11.2 ± 2.3 days. One-year survival was achieved in 95% of cases, two-year – in 81%, three-year – in 64%.Conclusion. Laparoscopic liver resections in hepatocellular carcinoma prove to be safe and provide satisfactory surgical and oncological outcomes.
- 15 December 2022
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 27 (4) , 23-30
Open AccessMinimally invasive surgery for hepatocellular carcinoma
Aim. To evaluate outcomes of laparoscopic liver resections in patients with hepatocellular carcinoma (HCC).Materials and methods. 40 endovideosurgical liver resections were performed in patients with HCC in the period of 2011–2021. Concomitant cirrhosis was detected in 36 cases (90%).Results. The average duration of surgery was 158.1 ± 78.6 min. The duration of anatomical lobar resections appeared to be the longest – 230 min. The average volume of intraoperative blood loss was 259.5 ± 260.5 ml, which almost excluded blood transfusions. The duration of hospitalization comprised 11.2 ± 2.3 days. One-year survival was achieved in 95% of cases, two-year – in 81%, three-year – in 64%.Conclusion. Laparoscopic liver resections in hepatocellular carcinoma prove to be safe and provide satisfactory surgical and oncological outcomes.